5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

SIGN UP TODAY

M E DI C A L DE V I C E M ARK E TS

Will GLP-1 Drugs Wake up the Sleep Apnea Market?

The popular new drug class could be a game changer for several medical device sectors, but GLP-1s won't
catch ResMed resting on its laurels.

Amanda Pedersen
May 8, 2024

5 Min Read

Initially approved to treat diabetes, glucagon-like peptide-1 (GLP-1) drugs like Ozempic are being heralded to
address obesity and, more recently, obstructive sleep apnea IMAGE CREDIT: MARIO TAMA / GETTY IMAGES NEWS

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 1/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

VIA GETTY IMAGES

The noise around GLP-1 drugs and their ripple effect on medtech continues to grow louder as
clinical data appears to support a growing use case for the drugs.

Initially approved to treat diabetes, glucagon-like peptide-1 (GLP-1) drugs are being heralded to
address obesity and, more recently, obstructive sleep apnea (OSA). But even if GLP-1s prove to
be disruptive to this medtech sector, the current market leader for CPAP machines is unlikely to
be caught resting on its laurels, if management and analyst commentary are any indication.

"We have long been believers that clinicians should turn to a variety of
drugs, devices, and procedures in the treatment of diseases."

In April, top-line data from Eli Lilly’s phase III SURMOUNT-OSA trial comparing the efficacy of
GLP-1s alone and in combination with positive airway pressure (PAP) in OSA patients over 12
months. Overall results were positive for both arms, with the PAP plus GLP-1 arm showing a
62.8% apnea-hypopnea index (AHI) reduction compared to a 55.0% AHI reduction from GLP-1
treatment alone. The results still managed to spark enough investor fear to trigger a 6% dip in
ResMed’s stock the day the results were released.

Analysts like William Blair’s Margaret Kazcor Andrew continue to be bullish that CPAP will remain
the gold standard for sleep apnea treatment, with GLP-1 drugs likely to be used as adjunctive
therapy.

Related: Hey Medtech, You Need to Calm Down (About GLP-1)

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 2/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

“...As we gather a more complete dataset over time, we expect these results to ultimately
conclude that the impact of these drugs on the market should not only be manageable but
ultimately help drive awareness of the disease and fuel an increase in the number of patients
who ultimately are offered various forms of treatment – in this case, positive airway pressure,”
Andrew wrote in a report published on April 18 based on a conversation with Carlos Nunez, MD,
ResMed’s chief medical officer, about the SURMOUNT-OSA trial results.

“At a high level, we have long been believers that clinicians should turn to a variety of drugs,
devices, and procedures in the treatment of diseases,” Andrew wrote. “These tools work in
combination and are often applied differently depending on the patient profile. The GLP-1 drugs
are the latest class to show a benefit in patients, this time with OSA, but like other tools have
nontrivial side effects, cost concerns, and patient persistence issues that balance out the
headline benefits.”

The size of the underlying patient populations, which are expected to surpass 1.3 billion globally
by 2050, as well as the under penetration of CPAP treatment, which Andrew ballparks at 15% or
less in many markets, reinforces the analyst’s argument.

Related: Abbott CEO: GLP-1 Concerns in Medtech Are Overblown

“No single treatment is likely to overwhelm the demonstrated benefits of CPAP given patient
access, complications, and patient falloff that has been observed with the GLP-1 agents to date,”
Andrew said.

ResMed CEO: Big Pharma is squarely focused on GLP-1 medications right

now

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 3/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

Image courtesy of ResMed

ResMed CEO Mick Farrell’s stance on the issue is that the latest advances in both Big Tech and
Big Pharma “can potentially bring incredible numbers of new patients into the healthcare system
where ResMed is uniquely positioned to provide ongoing care at home.”

“Patients are voting with their wallets and respiratory therapists and
physicians are voting with their recommendations and their
prescriptions.”

During the company’s first-quarter earnings call, Farrell said the company is laser-focused on
growing the market to help people get on the therapy they need and on a pathway to better sleep,
better health, and better long-term care.

During the quarter, ResMed introduced its latest sleep apnea mask innovation, the AirFit F40, into
the U.S. market. The F40 features a new technology the company calls AdaptiSeal, touted as a
silicone cushion designed to create and maintain a better facial seal even as the user moves
during sleep. The new mask leverages a fully flexible frame technology to cope with frequent
nocturnal movement, according to ResMed.

Related: Are Weight-Loss Drugs the da Vinci Robot’s Newest Competitor?

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 4/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

Image courtesy of ResMed

“Physicians, respiratory therapists, and patients love the F40 for its comfort, its fit, and its ease of
use,” Farrell said. “It is the smallest full-face mask on the market from ResMed. Patients are
voting with their wallets and respiratory therapists and physicians are voting with their
recommendations and their prescriptions.”

Where some medtech leaders might see GLP-1 drugs as a big threat to their territory, Farrell sees
it as an opportunity to funnel more people toward CPAP treatment by boosting awareness of
chronic diseases like sleep apnea, and driving more people who suffer from these diseases into
treatment pathways they may not have been previously open to or aware of, such as CPAP
machines. By this line of thinking, he said ResMed expects the GLP-1 trend to drive not just more
patients into the company’s channel, but also more motivated patients into its channel.

“Big Pharma is squarely focused on GLP-1 medications right now. For many people dealing with
their obesity, their healthcare goals are focused on losing weight while improving their diet,
exercise, and their sleep routines,” he said. “We believe that increased utilization of GLP-1s to
treat obesity will bring many new people into the healthcare funnel, activating them to see their
primary care physicians as they strive for weight loss and other medical health.”

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 5/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

Image courtesy of ResMed

ResMed has been tracking the impact of GLP-1s through a de-identified patient analysis using an
overlap of its own data and third-party claims data, Farrell said during the earnings call. He said
the company has now analyzed data on up to 660,000 subjects and the bottom line is that the
data show GLP-1s are having a positive impact on patients seeking and adhering to positive
airway pressure therapy.

“The latest numbers are an improvement from what we presented previously. For patients
prescribed a GLP-1 medication, the latest data show a 10.5% higher propensity to start positive
airway pressure therapy over those not taking the drug,” Farrell said. “These data show clearly
https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 6/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

that these new GLP-1 pharmaceutical class is actually a tailwind for our ResMed business,
bringing more patients and more motivated patients into the healthcare system.”

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical
device professionals connect the dots between the medtech news of the day and the bigger picture. She
has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

SUBSCRIBE TODAY

You May Also Like

MD+DI
M ed ica l Retracts Story
Devi ce Marke ts on Gaza Medical Facilities

October 12, 2023

MD+DI
M ed ica l Managing
Devi ce Marke Editor’s
ts Must-Attend List for BIOMEDevice
September 14, 2023

Stabilization
M ed ica l Devi ce in Medtech:
Marke ts Are We There Yet?
June 07, 2023

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 7/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?
M ed ica l Devi ce Marke ts
Letting the Marketing Cat out of the Medtech Bag

May 22, 2023

Editors' Choice
REGULATORY & QUALITY
Philips Respironics Trilogy Evo Ventilator Recall Identified as Class I

MAY 13, 2024

DIGITAL HEALTH
Big Tech in Medtech: Is Apple Pressing Too Hard?

MAY 13, 2024

SPONSORED CONTENT
Designing the Next Generation of Surgical Robotics

MAY 21, 2024

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 8/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

Recent Headlines

Philips Respironics Trilogy Evo Ventilator Recall Identified as Class I

MAY 14, 2024 | 3 MIN READ

Big Tech in Medtech: Is Apple Pressing Too Hard?

MAY 14, 2024 | 3 MIN READ

Designing the Next Generation of Surgical Robotics

MAY 21, 2024 | 14:00 EDT

Route 92 Medical Recalls Catheters After Distal Tip Separation

MAY 11, 2024 | 2 MIN READ

Our Network Events

Battery Technology MD&M West

Design News MD&M East

Packaging Digest MD&M Minneapolis

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 9/10
5/14/24, 7:44 AM Will GLP-1 Drugs Disrupt the Sleep Apnea Market?

Plastics Today MD&M South

Powder & Bulk Solids BIOMEDevice Boston

Qmed+ BIOMEDevice Silicon Valley

More Events

Connect Join Us

About
SUBSCRIBE TODAY
Advertise

FAQ
Follow Us
Content Licensing & Reprints

Informa Markets - Engineering Portfolio

Copyright © 2024 All rights reserved. Informa Markets, a trading division of Informa PLC.

Accessibility | Privacy Policy | Cookie Policy | Terms of use | Visitor Terms and Conditions

https://www.mddionline.com/medical-device-markets/will-glp-1-drugs-wake-up-the-sleep-apnea-market- 10/10